ENHANCE trial

ENHANCE trial
Name	ENHANCE trial

ENHANCE trial. The ENHANCE trial was a major randomized controlled trial in cardiology that investigated the effect of combining two lipid-lowering medications on the progression of atherosclerosis. Sponsored by Merck & Co. and Schering-Plough, the study compared the combination of ezetimibe and simvastatin against simvastatin alone in patients with heterozygous familial hypercholesterolemia. Its unexpected results, which showed no additional benefit on a key imaging endpoint, sparked significant controversy within the medical community and led to intense scrutiny from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency.

Background and rationale

The trial was conceived during a period of intense focus on aggressively lowering low-density lipoprotein cholesterol to reduce cardiovascular disease risk. Ezetimibe, marketed as Zetia, worked by inhibiting cholesterol absorption in the intestine via the NPC1L1 protein, offering a novel mechanism distinct from statins like simvastatin. The combination product, known as Vytorin, was jointly developed by Merck & Co. and Schering-Plough and had gained widespread use based on its potent LDL-lowering effects. Researchers hypothesized that this greater reduction in LDL cholesterol would translate into a measurable slowing of carotid intima-media thickness progression, a validated surrogate endpoint for atherosclerotic burden, in high-risk patients with familial hypercholesterolemia. This hypothesis was supported by prior studies like the ASCOT trial and METEOR trial, which linked statin therapy to changes in CIMT.

Study design and methods

ENHANCE was a multicenter, randomized, double-blind study conducted at various sites including the Academic Medical Center in Amsterdam. It enrolled 720 patients with heterozygous familial hypercholesterolemia, a genetic disorder causing severely elevated LDL cholesterol. Participants were randomized to receive either a daily combination of ezetimibe (10 mg) and simvastatin (80 mg) or simvastatin (80 mg) alone. The primary endpoint was the change in mean carotid intima-media thickness measured by B-mode ultrasound over a 24-month period. Secondary endpoints included various lipid profile measurements and assessments of cardiovascular events. The trial's design and statistical analysis plan were overseen by a steering committee that included prominent cardiologists like Dr. John Kastelein.

Results and primary findings

The trial results, announced in January 2008, were strikingly negative. Despite the combination therapy producing a significantly greater reduction in LDL cholesterol compared to simvastatin monotherapy, there was no statistically significant difference in the progression of carotid intima-media thickness between the two treatment groups. In fact, the CIMT measurements showed a slight, non-significant increase in the combination group. This dissociation between a potent lipid-lowering effect and the lack of benefit on the surrogate endpoint challenged a fundamental assumption in preventive cardiology. The findings were later published in the New England Journal of Medicine and presented at major conferences like the American College of Cardiology annual meeting.

Controversy and criticism

The release of the results triggered immediate and widespread controversy. A major point of contention was a significant delay in the completion and public reporting of the trial data, which occurred nearly two years after the study ended, prompting investigations by the U.S. House of Representatives Committee on Energy and Commerce. Critics, including prominent cardiologists like Dr. Steven Nissen of the Cleveland Clinic, argued that the extensive use of Vytorin was not supported by outcomes trial evidence demonstrating a reduction in myocardial infarction or stroke. The medical community debated the validity of CIMT as a surrogate and whether the trial population, with many participants already on pre-trial statin therapy, was suitable for detecting a treatment effect. The handling of the data by the sponsors, Merck & Co. and Schering-Plough, was heavily scrutinized.

Impact and regulatory response

The controversy had a direct impact on clinical practice and regulatory oversight. Prescriptions for Vytorin and Zetia declined sharply following the news. Regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, reviewed the data but did not mandate a withdrawal of the drugs, instead requiring updates to their prescribing information to reflect the ENHANCE results. The FDA emphasized that lipid-lowering drugs should ultimately be judged by their effect on cardiovascular events, not surrogate markers. The event accelerated calls for greater transparency in clinical trial reporting and contributed to the policies of organizations like the International Committee of Medical Journal Editors.

Subsequent research and legacy

The definitive answer regarding ezetimibe's impact on cardiovascular outcomes came from later, large-scale trials. The IMPROVE-IT trial, published in 2015, demonstrated that adding ezetimibe to simvastatin did indeed produce a modest but significant reduction in major cardiovascular events in patients post-acute coronary syndrome. This study validated the LDL hypothesis but confirmed that the relationship between LDL lowering and atherosclerosis progression, as measured by CIMT, was more complex than previously thought. The ENHANCE trial remains a landmark case study in the limitations of surrogate endpoints, the importance of outcomes data, and the critical need for timely dissemination of clinical trial results. Its legacy influenced the design and interpretation of subsequent cardiovascular outcome trials for newer agents like the PCSK9 inhibitors.

Category:Clinical trials Category:Cardiology Category:Medical controversies